Related content

Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model

By        

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1087-1093

Spandidos Publications

Access to resources Recommend Favorite

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

By Kerklaan Bojana   Diéras Veronique   Tourneau Christophe   Mergui-Roelvink Marja   Huitema Alwin   Rosing Hilde   Beijnen Jos   Marreaud Sandrine   Govaerts Anne-Sophie   Piccart-Gebhart Martine   Schellens Jan   Awada Ahmad  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 53-62

Springer Publishing Company

Access to resources Recommend Favorite

Mechanisms of Trastuzumab Resistance in Breast Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 3, 2009-03 ,pp. : 348-355

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

By Norum J.   Olsen J. A.   Wist E. A.   Lønning P. E.  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells

By Nahta Rita   Esteva Francisco  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 2, 2004-02 ,pp. : 186-190

Springer Publishing Company

Access to resources Recommend Favorite